Characterization of PI (breast cancer cell special peptide) in MDA-MB-231 breast cancer cells and its potential therapeutic applications

International Journal of Oncology

Volumn 47, Issue 4, 2015, Pages 1371-1378

  Gao, Change ^a   Hong, Min ^a   Geng, Jiwei ^a   Zhou, Huahua ^a   Dong, Jian ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; HSV TK GCV; PI; Targeted therapy

Indexed keywords

DRUG CARRIER; GANCICLOVIR; HYBRID PROTEIN; PI PEPTIDE; PI PEPTIDE THYMIDINE KINASE FUSION PROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; GONAD-SPECIFIC TRANSPORTER, HUMAN; ORGANIC ANION TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL VIABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEMALE; HEART; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; KIDNEY; LIVER; LUNG; MUSCLE; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; STOMACH; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; HUMAN; MOUSE; PROCEDURES; SUICIDE TRANSGENE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; FLUORESCENT ANTIBODY TECHNIQUE; GANCICLOVIR; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; ORGANIC ANION TRANSPORTERS; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84940982386     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3140     Document Type: Article

References (30)

1. Aguas F, Martins A, Gomes TP, de Sousa M and Silva DP; Portuguese Menopause Society and Portuguese Gynaecology Society: Prophylaxis approach to a-symptomatic post-menopausal women: Breast cancer. Maturitas 52 (Suppl 1): S23-S31, 2005.
2. Dumitrescu RG and Cotarla I: Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med 9: 208-221, 2005.
3. O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A and Oakes SR: Therapeutic targets in triple negative breast cancer. J Clin Pathol 66: 530-542, 2013.
4. Hurley J, Reis IM, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R and Pegram MD: The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: Retrospective analysis of 144 patients. Breast Cancer Res Treat 138: 783-794, 2013.
5. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, et al: Treatment of triple-negative breast cancer using anti-EGFRdirected radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med 54: 913-921, 2013.
6. Rodler E, Korde L and Gralow J: Current treatment options in triple negative breast cancer. Breast Dis 32: 99-122, 2010.
7. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S: Treatment of triple negative breast cancer (TNBC): Current options and future perspectives. Cancer Treat Rev 36 (Suppl 3): S80-S86, 2010.
8. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, et al: Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27: 2705-2711, 2009.
9. Helleday T, Bryant HE and Schultz N: Poly (ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4: 1176-1178, 2005.
10. Koren E and Torchilin VP: Cell-penetrating peptides: Breaking through to the other side. Trends Mol Med 18: 385-393, 2012.
11. Ryu JS, Kuna M and Raucher D: Penetrating the cell membrane, thermal targeting and novel anticancer drugs: The development of thermally targeted, elastin-like polypeptide cancer therapeutics. Ther Deliv 5: 429-445, 2014.
12. Dong J, Liu W, Jiang A, Zhang K and Chen M: A novel peptide, selected from phage display library of random peptides, can efficiently target into human breast cancer cell. Chin Sci Bull 53: 860-867, 2008.
13. Zadeh G, Qian B, Okhowat A, Sabha N, Kontos CD and Guha A: Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol 164: 467-476, 2004.
14. De Palma M, Venneri MA and Naldini L: In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 14: 1193-1206, 2003.
15. Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179-1188, 1988.
16. Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193, 1988.
17. Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, Wu M, Zhou Z and Qian M: targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Mol Cancer Res 8: 135-144, 2010.
18. Li ZJ, Wu WKK, Ng SSM, Yu L, Li HT, Wong CC, Wu YC, Zhang L, Ren SX, Sun XG, et al: A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J Control Release 148: 292-302, 2010.
19. Zhang L, Yin G, Yan D, Wei Y, Ma C, Huang Z, Liao X, Yao Y, Chen X and Hao B: In vitro screening of ovarian tumor specific peptides from a phage display peptide library. Biotechnol Lett 33: 1729-1735, 2011.
20. Yu Z, Wu J, Wu S, Jia P, Tong Y, Wu X and Wang Y: A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth. Cancer Lett 279: 101-107, 2009.
21. Hu M, Wang J, Chen P and Reilly RM: HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclindependent kinase inhibitor p21WAF-1/CIP-1. Bioconjug Chem 17: 1280-1287, 2006.
22. Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A and Schroeder JA: Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 15: 100-109, 2009.
23. Massodi I, Bidwell GL III, Davis A, Tausend A, Credit K, Flessner M and Raucher D: Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metastasis 26: 251-260, 2009.
24. Bidwell GL III, Davis AN and Raucher D: Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 135: 2-10, 2009.
25. Harada H, Hiraoka M and Kizaka-Kondoh S: Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018, 2002.
26. Takada Y, Singh S and Aggarwal BB: Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 279: 15096-15104, 2004.
27. Tan M, Lan K-H, Yao J, Lu CH, Sun M, Neal CL, Lu J and Yu D: Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66: 3764-3772, 2006.
28. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, et al: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 43: 22-26, 2000.
29. Zhao H, Wang J-C, Sun Q-S, Luo C-L and Zhang Q: RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 17: 10-18, 2009.
30. Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T and Kruse CA: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther 9: 87-95, 2002.